2025-04-30
魅丽纬叶成立于2013年,聚焦微创介入治疗领域,核心产品Netrod星带肾动脉射频消融系统获NMPA批准上市,用于难治性高血压治疗。其技术平台涵盖射频、超声及脉冲电场等能量形式,产品已取得CE认证和FDA突破性医疗器械认证,并完成海外首台手术,展现全球化潜力。公司以“微创技术解决慢病治疗痛点”为愿景,持续拓展糖尿病、心衰等疾病领域的创新疗法。
励楷科技
瑞博生物成立于2007年,是中国小核酸药物领域的领军企业,专注于RNA干扰技术开发。公司六款自研siRNA药物处于临床试验阶段,核心产品RBD4059(抗血栓)和RBD5044(降血脂)分别以“全球首款”和“最佳潜力”为亮点。瑞博生物凭借高效研发体系,实现从靶点发现到临床申报仅20个月,近期向港交所递交上市申请,加速推进心血管、代谢及肝病等慢病治疗管线的国际化布局。
恒旭资本(中基协备案号:P1070270)于2019年成立。作为上海汽车集团股份有限公司(简称“上汽集团”,600104.SH)金融平台上海汽车集团金控管理有限公司(简称“上汽金控”)旗下私募股权投资机构,依托上汽集团整体产业优势和上汽金控高效协同赋能,恒旭资本努力为上汽集团创新产业链的发展和出行生态圈的完善做出贡献。恒旭资本股权投资板块致力于布局绿色出行、出行生态、健康生态战略新兴产业,另类投资板块重点关注光伏和储能领域的优质资产。公司愿景是让投资人获得良好收益的同时,实现环境、社会、治理(“ESG”)协同发展,并致力于成为受人尊敬的优秀产业资本和受人信赖的一流投资机构。
恒旭资本累计管理规模已超过400亿元,投资人包括产业龙头、金融机构、国家政府、市场机构等。核心团队有丰富的产业资源,在项目管理、基金管理方面拥有丰富的经验,主导了宁德时代、地平线、捷氢科技、通行宝、清陶能源、芯旺微、亚虹医药、帅克宠物等数十个优质企业投资,陪伴企业成长为细分市场的龙头企业。
上一篇: 恒旭被投企业清能互联完成超2亿元战略融资
下一篇:没有了
Change of Address Notice
Dear investors and partners,
With your ongoing care and support, Hengxu Capital has achieved significant development and progress since its establishment. In order to better meet the needs of our business operations, our office location will be relocated to 5F, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai(Map Link: https://j.map.baidu.com/b5/x7VK).
The new office space is conveniently located with excellent facilities, providing improved conditions for meetings, receptions, and work. This relocation will facilitate better communication and collaboration between Hengxu Capital and our partners, enhancing employee satisfaction and office efficiency, and laying a solid foundation for continued and rapid business development.
The new office has been officially in use since January 29, and our mailing address has been switched to the new location. Considering the approaching Chinese New Year, we will not hold a relocation ceremony at the moment but plan to invite you to visit and guide us at a suitable time in the future.
If you have any questions or concerns, please feel free to contact us. Our phone numbers and email addresses remain unchanged. Once again, we appreciate your support and understanding, and we look forward to creating a brighter future together.
Shanghai SAIC Hengxu Capital Co., Ltd.
Jan. 29, 2024